clients, partners and patients to develop new treatments for NASH, diabetes and obesity.
Clinical Development and Regulatory Strategy + State-of-the-Art Clinical Facility + Full Scope CRO Services + Global Scientific Network
ProSciento Expands Asia Pacific Operations with Office in Australia Read More »
ProSciento CEO to Present at the European Association for the Study of the Liver (EASL) NAFLD Summit Read More »
View Our Presentation
Pathophysiology of Cardiovascular Disease in Diabetes Mellitus Read More »
Single Dose Euglycemic Clamp Studies Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between MK-1293 Insulin Glargine and Originator Insulin Glargine (Lantus) in Type 1 Diabetes and Healthy Subjects Read More »
FDA approves Ozempic to improve glycemic control in adults with T2D Read More »